Aspen Grove Capital LLC Sells 2,519 Shares of VanEck Biotech ETF $BBH

Aspen Grove Capital LLC trimmed its position in shares of VanEck Biotech ETF (NASDAQ:BBH) by 33.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,919 shares of the company’s stock after selling 2,519 shares during the period. Aspen Grove Capital LLC owned approximately 0.25% of VanEck Biotech ETF worth $925,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in BBH. Northwestern Mutual Wealth Management Co. increased its holdings in VanEck Biotech ETF by 40,463.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 494,061 shares of the company’s stock valued at $93,506,000 after buying an additional 492,843 shares during the period. Raymond James Financial Inc. lifted its holdings in shares of VanEck Biotech ETF by 2.8% during the 3rd quarter. Raymond James Financial Inc. now owns 69,809 shares of the company’s stock worth $11,566,000 after acquiring an additional 1,869 shares during the period. Ascent Advisors LLC bought a new position in shares of VanEck Biotech ETF during the 1st quarter worth about $11,178,000. Bank of America Corp DE boosted its position in shares of VanEck Biotech ETF by 17.7% during the 2nd quarter. Bank of America Corp DE now owns 52,466 shares of the company’s stock valued at $8,042,000 after acquiring an additional 7,898 shares in the last quarter. Finally, LPL Financial LLC boosted its position in shares of VanEck Biotech ETF by 63.5% during the 4th quarter. LPL Financial LLC now owns 31,813 shares of the company’s stock valued at $6,021,000 after acquiring an additional 12,351 shares in the last quarter. Institutional investors and hedge funds own 32.05% of the company’s stock.

VanEck Biotech ETF Price Performance

NASDAQ:BBH opened at $204.03 on Friday. VanEck Biotech ETF has a 12-month low of $156.45 and a 12-month high of $212.54. The firm has a 50-day moving average price of $194.35 and a 200 day moving average price of $192.32.

Insiders Place Their Bets

In other news, major shareholder Sardar Biglari sold 11,000 shares of the company’s stock in a transaction that occurred on Friday, July 17th. The stock was sold at an average price of $16.71, for a total value of $183,810.00. Following the sale, the insider directly owned 3,538,961 shares in the company, valued at approximately $59,136,038.31. This represents a 0.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold 21,493 shares of company stock worth $359,145 over the last 90 days.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.